Targeting KRAS-interacting SNAREs with a SNAP23-degrading protease thus also impairs tumorigenesis, further indicating that targeting SNARE proteins may represent a alternative therapeutic opportunity in KRAS-driven cancer. The gene discussed is SNAP23; the disease is cancer.